

Inside the Issue: Targeted and Immunotherapeutic Approaches for Biliary Tract Cancers

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What was the approximate objective response rate (ORR) observed with futibatinib for patients with previously treated intrahepatic cholangiocarcinoma with FGFR2 rearrangements in the Phase II FOENIX-CCA2 trial?
 - a. 12%
 - b. 22%
 - c. 42%**
 - d. 62%
2. IDH1 mutations are most common in which of the following diseases?
 - a. Intrahepatic cholangiocarcinoma**
 - b. Extrahepatic cholangiocarcinoma
 - c. Incidence is similar in intrahepatic and extrahepatic cholangiocarcinoma
3. What was the approximate confirmed ORR with the combination of tucatinib/trastuzumab for patients with HER2-positive metastatic biliary tract cancer in the Phase II SGNTUC-019 basket trial?
 - a. 17%
 - b. 27%
 - c. 47%**
 - d. 67%
4. The bispecific antibody zanidatamab targets which of the following antigens?
 - a. CD3/FGFR2
 - b. CD3/HER2
 - c. Two domains on FGFR2
 - d. Two domains on HER2**
5. Which of the following adverse events is most commonly associated with FGFR inhibitors?
 - a. Hyponatremia
 - b. Hyperphosphatemia**
 - c. Viral infections
 - d. Hemorrhage